Toronto Dominion Bank bought a new stake in shares of Palvella Therapeutics (NASDAQ:PVLA - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 13,211 shares of the company's stock, valued at approximately $159,000. Toronto Dominion Bank owned about 0.12% of Palvella Therapeutics at the end of the most recent quarter.
Other institutional investors also recently made changes to their positions in the company. Citadel Advisors LLC acquired a new stake in shares of Palvella Therapeutics during the 4th quarter valued at $125,000. Geode Capital Management LLC acquired a new position in shares of Palvella Therapeutics in the fourth quarter worth $171,000. Cresset Asset Management LLC acquired a new position in shares of Palvella Therapeutics in the fourth quarter worth $251,000. Renaissance Technologies LLC acquired a new position in shares of Palvella Therapeutics in the fourth quarter worth $256,000. Finally, BML Capital Management LLC acquired a new position in shares of Palvella Therapeutics in the fourth quarter worth $506,000. 40.11% of the stock is owned by institutional investors.
Analyst Upgrades and Downgrades
PVLA has been the topic of several analyst reports. TD Cowen initiated coverage on shares of Palvella Therapeutics in a research report on Wednesday, February 5th. They set a "buy" rating and a $44.00 target price on the stock. HC Wainwright restated a "buy" rating and set a $38.00 price target on shares of Palvella Therapeutics in a research note on Wednesday, April 30th. Stifel Nicolaus started coverage on shares of Palvella Therapeutics in a report on Wednesday, March 26th. They issued a "buy" rating and a $45.00 price target for the company. Chardan Capital began coverage on shares of Palvella Therapeutics in a report on Wednesday, April 9th. They issued a "buy" rating and a $50.00 price target for the company. Finally, Jones Trading started coverage on shares of Palvella Therapeutics in a research report on Tuesday, March 25th. They set a "buy" rating and a $45.00 target price for the company. Seven investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, Palvella Therapeutics presently has an average rating of "Buy" and an average price target of $46.29.
Read Our Latest Stock Report on PVLA
Palvella Therapeutics Price Performance
Shares of PVLA stock traded down $0.32 during trading on Thursday, reaching $23.49. 48,196 shares of the company's stock traded hands, compared to its average volume of 69,041. The company has a market capitalization of $259.71 million, a P/E ratio of -1.94 and a beta of -0.10. The stock has a 50-day moving average price of $23.45. Palvella Therapeutics has a 1 year low of $6.20 and a 1 year high of $29.27.
Palvella Therapeutics (NASDAQ:PVLA - Get Free Report) last released its earnings results on Thursday, May 15th. The company reported ($0.74) EPS for the quarter, beating the consensus estimate of ($3.40) by $2.66. Equities research analysts forecast that Palvella Therapeutics will post -3.69 EPS for the current year.
Insiders Place Their Bets
In related news, Director George M. Jenkins acquired 2,500 shares of the firm's stock in a transaction dated Wednesday, April 9th. The stock was purchased at an average cost of $20.13 per share, with a total value of $50,325.00. Following the completion of the acquisition, the director now directly owns 183,171 shares of the company's stock, valued at approximately $3,687,232.23. This trade represents a 1.38% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. Corporate insiders own 20.50% of the company's stock.
Palvella Therapeutics Company Profile
(
Free Report)
Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc, formerly known as Pieris Pharmaceuticals Inc, is based in WAYNE, Pa.
Further Reading
Before you consider Palvella Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Palvella Therapeutics wasn't on the list.
While Palvella Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
